Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

Ergomed to present at the International Society of Pharmacovigilance's Intelligent Automation

Can automated processes powered by artificial intelligence provide effective solutions to the ever-increasing challenges in pharmacovigilance?

Ergomed Plc (LON:ERGO) said its pharmacovigilance subsidiary PrimeVigilance will be organising and presenting at the International Society of Pharmacovigilance's Intelligent Automation in Pharmacovigilance seminar.

The seminar will be held at Biogen's headquarters in Cambridge, Massachusetts, from 4-5 December 2017. It will seek to answer the question: Can automated processes powered by artificial intelligence provide effective solutions to the ever-increasing challenges in pharmacovigilance?

PrimeVigilance's chief executive officer, Jan Petracek, will be presenting the results from the company’s successful pilot project demonstrating how robotic process automation of selected pharmacovigilance systems can increase efficiency by up to 400 times, increasing speed, reducing cost and improving accuracy.

PrimeVigilance is working on the early deployment of robots in its operations.

"PrimeVigilance has consistently demonstrated growth, which is in no small part due to our market-leading adoption of new techniques and technologies and we are at the forefront of robotic automation, the next leap forward in technology for our industry,” Petracek said.

READ: Ergomed hopes to have PeproStat on the market by 2020 as it sails through Phase II trials

“We look forward to discussing these advances in pharmacovigilance automation and how they can increase efficiency and accuracy. Pharmacovigilance is an extremely fast-growing and highly regulated market and we are pleased to be able to share our views on meeting these increasingly complex regulatory requirements," he added.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK